M Frantz

502 total citations
9 papers, 320 citations indexed

About

M Frantz is a scholar working on Pediatrics, Perinatology and Child Health, Pharmacology and Analytical Chemistry. According to data from OpenAlex, M Frantz has authored 9 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pediatrics, Perinatology and Child Health, 3 papers in Pharmacology and 2 papers in Analytical Chemistry. Recurrent topics in M Frantz's work include Pharmacological Effects and Toxicity Studies (4 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and Pharmaceutical studies and practices (3 papers). M Frantz is often cited by papers focused on Pharmacological Effects and Toxicity Studies (4 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and Pharmaceutical studies and practices (3 papers). M Frantz collaborates with scholars based in Malaysia and United States. M Frantz's co-authors include A. Arthur Sugerman, Edward A. Swabb, S. M. Singhvi, DA Willard, Kenneth L. Duchin, David A Willard, James Manning, Michelle Stern, Mariana C. Stern and Michael A. Ross and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Clinical Pharmacology & Therapeutics and American Journal of Neuroradiology.

In The Last Decade

M Frantz

9 papers receiving 260 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M Frantz Malaysia 7 152 76 65 60 44 9 320
I R Welshman United States 12 293 1.9× 33 0.4× 53 0.8× 79 1.3× 79 1.8× 21 663
V. Malerczyk Germany 15 262 1.7× 42 0.6× 73 1.1× 102 1.7× 71 1.6× 46 575
M. Verho Germany 13 177 1.2× 170 2.2× 41 0.6× 75 1.3× 83 1.9× 54 621
RA Blouin United States 8 227 1.5× 26 0.3× 68 1.0× 23 0.4× 53 1.2× 9 474
D Höffler Germany 11 265 1.7× 29 0.4× 70 1.1× 88 1.5× 85 1.9× 83 453
Gail L. Jungbluth United States 12 432 2.8× 46 0.6× 45 0.7× 124 2.1× 114 2.6× 21 777
Juliana F. Roos Australia 8 151 1.0× 41 0.5× 55 0.8× 61 1.0× 91 2.1× 12 617
Alfred Chin United States 10 161 1.1× 23 0.3× 28 0.4× 86 1.4× 54 1.2× 30 349
Mia Parsonnet United States 7 197 1.3× 13 0.2× 54 0.8× 66 1.1× 67 1.5× 11 397
T. B. Tjandramaga Belgium 15 373 2.5× 96 1.3× 179 2.8× 72 1.2× 66 1.5× 41 818

Countries citing papers authored by M Frantz

Since Specialization
Citations

This map shows the geographic impact of M Frantz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Frantz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Frantz more than expected).

Fields of papers citing papers by M Frantz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Frantz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Frantz. The network helps show where M Frantz may publish in the future.

Co-authorship network of co-authors of M Frantz

This figure shows the co-authorship network connecting the top 25 collaborators of M Frantz. A scholar is included among the top collaborators of M Frantz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Frantz. M Frantz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Duchin, Kenneth L., et al.. (1991). Pharmacokinetics, Safety, and Pharmacologic Effects of Fosinopril Sodium, an Angiotensin‐Converting Enzyme Inhibitor in Healthy Subjects. The Journal of Clinical Pharmacology. 31(1). 58–64. 32 indexed citations
2.
Singhvi, S. M., et al.. (1988). Disposition of fosinopril sodium in healthy subjects.. British Journal of Clinical Pharmacology. 25(1). 9–15. 83 indexed citations
3.
Duchin, Kenneth L., Burton P. Drayer, Michael A. Ross, Susan Allen, & M Frantz. (1986). Pharmacokinetics of lopamidol after intrathecal administration in humans.. American Journal of Neuroradiology. 7(5). 895–898. 5 indexed citations
4.
Frantz, M, et al.. (1985). Pharmacokinetics of aztreonam in elderly male volunteers.. British Journal of Clinical Pharmacology. 19(2). 233–237. 13 indexed citations
5.
Stern, Mariana C., et al.. (1985). Aztreonam in human serum and breast milk.. British Journal of Clinical Pharmacology. 19(4). 509–511. 19 indexed citations
6.
Swabb, Edward A., et al.. (1983). Metabolism and pharmacokinetics of aztreonam in healthy subjects. Antimicrobial Agents and Chemotherapy. 24(3). 394–400. 59 indexed citations
7.
Swabb, Edward A., et al.. (1983). Renal handling of the monobactam azthreonam in healthy subjects. Clinical Pharmacology & Therapeutics. 33(5). 609–614. 16 indexed citations
8.
Swabb, Edward A., et al.. (1982). Single-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects. Antimicrobial Agents and Chemotherapy. 21(6). 944–949. 90 indexed citations
9.
Frantz, M, et al.. (1951). Observations on the toxicity of 3,3-diethyl-2,4-diketotetrahydropyridine (presidon).. PubMed. 9(2). 303–13. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026